Angiotensin II formation in human vasculature after chronic ACE inhibition: A prospective, randomized, placebo-controlled study

Cardiovascular Drugs and Therapy

Volumn 14, Issue 1, 2000, Pages 55-60

  Oosterga, Margreeth ^c   Voors, Adriaan A ^c   Buikema, Hendrik ^c   Pinto, Yigal M ^c   Haber, Harry E ^a   Ebels, Tjark ^c   Morshuis, Wim J ^c   Kingma, J Herre ^c   Crijns, Harry J G M ^c   Van Gilst, Wiek H ^b  

^a PFIZER INC   (United States)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c NONE

Author keywords

ACE inhibition; Angiotensin; Endothelial factors; Renin angiotensin system; Vasculature

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN I; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; QUINAPRIL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MAMMARY ARTERY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASCULARIZATION;

ADMINISTRATION, ORAL; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENIN-ANGIOTENSIN SYSTEM; SINGLE-BLIND METHOD;

EID: 0345057816     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007843205311     Document Type: Article

References (21)

1. 1. Dzau VJ. Significance of the vascular renin-angiotensin pathway. Hypertension 1986;8:553-559.
2. 2. Lindpaintner K, Ganten D. The cardiac renin-angiotensin system. An appraisal of present experimental and clinical evidence. Circ Res 1991;68:905-921.
3. 3. Hirsch AT, Pinto YM, Schunkert H, Dzau VJ. Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure. Am J Cardiol 1990;66: 22D-32D.
4. 4. Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ. Tissue specific activation of cardiac angiotensin-converting enzyme in experimental heart failure. Circ Res 1991;69:475-482.
5. 5. Schelling P, Fischer H, Ganten D. Angiotensin and cell growth: a link to cardiovascular hypertrophy? J Hypertens 1991;9:3-15.
6. 6. Schiffrin EL, Deng LY, Larochelle P. A prospective trial of effects of converting enzyme inhibitor vs a beta-blocker on structure and function of resistance arteries form mild hypertensive patients. J Hypertens 1994;12(Suppl. 3):S70-S88.
7. 7. Nakashima Y, Fouad FM, Tarazi RZ. Regression of left ventricular hypertrophy from systemic hypertension by enalapril. Am J Cardiol 1984;53:1044-1049.
8. 8. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction - results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-677.
9. 9. Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987;316:1429-1435.
10. 10. Buikema H, Pinto YM, Rooks G, Grandjean JG, Gilst van WH. The deletion polymorphism of the angiotensin-converting enzyme gene is related to phenotypic differences in human arteries. Eur Heart J 1996;17:787-794.
11. 11. Buikema H, Pinto YM, Geel van PP, et al. Differential inhibition of plasma versus tissue ACE by utibapril: biochemical and functional evidence for inhibition of vascular ACE activity. J Cardiovasc Pharmacol 1997;29:684-691.
12. 12. Voors AA, Pinto YM, Buikema H, et al. Dual pathway for angiotensin II formation in human internal mammary arteries. Br J Pharmacol 1998;125:1028-1032.
13. 13. Long Zhuo J, Froomes P, Casley D, et al. Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease. Circulation 1997;96: 174-182.
14. 14. Mancini J, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND study. Circulation 1996;94:258-265.
15. 15. Sedman AJ, Posvar E. Clinical pharmacology of quinapril in healthy volunteers and in patients with hypertension and congestive heart failure. Angiology 1989;40:360-369.
16. 16. Nussberger J, Waeber G, Waeber B, Bidiville J, Brunner HR. Plasma angiotensin-(1-8) octapeptide measurement to assess acute angiotensin-converting enzyme inhibition with captopril administered parenterally to normal subjects. J Cardiovasc Pharmacol 1988;11:716-721.
17. 17. Schnaper HW. Comparison of the efficacy and safety of quinapril vs captopril in treatment of moderate to severe hypertension. Angiology 1989;40:389-395.
18. 18. Okunishi H, Oka Y, Shioto N, Kawanoto T, Song K, Miyazaki M. Marked species-difference in the vascular angiotensin II-forming pathway: Humans versus rodents. Jpn J Pharmacol 1993;62:207-210.
19. 19. Skidgel RA, Erdos EG. Biochemistry of angiotensin converting enzyme. In: Robertson HS, Nicolls MG, eds. The Renin-Angiotensin System. London: Gower Medical Publishers, 1993.
20. 20. Gavras I. Bradykinin-mediated effects of ACE-inhibition. Kidney Int 1992;42:1020-1029.
21. 21. Auch-Schwelk W, Bossaller C, Claus M, Graf M, Fleck E. ACE inhibitors are endothelium dependent vasodilators of coronary arteries during submaximal stimulation with bradykinin. Cardiovasc Res 1993;27:312-317.